All posts

Follow Us

LinkedInInstagramX
Quarterly ResultsArchiveLast updated 22 November 20263 min read

Astonea Labs (ASTONEALAB) Profit Soars 150% as Margins Jump in Q2 FY27

The API maker's revenue grew 45.5% year-on-year, while net profit margin expanded by 220 basis points, driven by a higher share of own OTC brands.

By Abhinav Swaroop, CFA, Chief Business Officer: Hexawealth · Created 16 November 2026

Astonea Labs reported a 150% surge in net profit for Q2 FY27, on a 45.5% rise in revenue. Margins expanded sharply as the company's own over-the-counter brands gained traction, with management guiding for over ₹215 crore in revenue this fiscal year.

For a pharmaceutical company building its own brands, the shift from contract manufacturing to higher-margin sales is the critical turn. Astonea Labs' September quarter shows that pivot taking hold, with profit growth far outpacing a strong top line as its own over-the-counter portfolio gains ground.

The numbers tell a story of accelerating momentum. Revenue hit ₹96 crore, up 45.5% from a year ago and 18.5% from the prior quarter. Net profit tripled year-on-year to ₹5 crore, and the net profit margin expanded to 5.2%, a 220-basis-point improvement.

Revenue & profit

Revenue (₹ Cr)

Profit (₹ Cr)

Revenue & profitQ2 FY25 47.0, Q2 FY26 66.0, Q4 FY26 81.0, Q2 FY27 96.0. Q2 FY25 2.0, Q2 FY26 2.0, Q4 FY26 3.0, Q2 FY27 5.0050100150200Q2 '25Q2 '26Q4 '26Q2 '27
  • Revenue (₹ Cr), Q2 FY25: 47.0
  • Revenue (₹ Cr), Q2 FY26: 66.0
  • Revenue (₹ Cr), Q4 FY26: 81.0
  • Revenue (₹ Cr), Q2 FY27: 96.0
  • Profit (₹ Cr), Q2 FY25: 2.0
  • Profit (₹ Cr), Q2 FY26: 2.0
  • Profit (₹ Cr), Q4 FY26: 3.0
  • Profit (₹ Cr), Q2 FY27: 5.0

Revenue (₹ Cr)

Revenue (₹ Cr)Q2 FY25 47.0, Q2 FY26 66.0, Q4 FY26 81.0, Q2 FY27 96.0050100150200Q2 '25Q2 '26Q4 '26Q2 '27
  • Revenue (₹ Cr), Q2 FY25: 47.0
  • Revenue (₹ Cr), Q2 FY26: 66.0
  • Revenue (₹ Cr), Q4 FY26: 81.0
  • Revenue (₹ Cr), Q2 FY27: 96.0

Profit (₹ Cr)

Profit (₹ Cr)Q2 FY25 2.0, Q2 FY26 2.0, Q4 FY26 3.0, Q2 FY27 5.002468Q2 '25Q2 '26Q4 '26Q2 '27
  • Profit (₹ Cr), Q2 FY25: 2.0
  • Profit (₹ Cr), Q2 FY26: 2.0
  • Profit (₹ Cr), Q4 FY26: 3.0
  • Profit (₹ Cr), Q2 FY27: 5.0

Net Profit Margin

Net Profit MarginQ2 FY25 4.3%, Q2 FY26 3.0%, Q4 FY26 3.7%, Q2 FY27 5.2%0%2%4%6%8%Q2 '25Q2 '26Q4 '26Q2 '27
  • Net Profit Margin, Q2 FY25: 4.3%
  • Net Profit Margin, Q2 FY26: 3.0%
  • Net Profit Margin, Q4 FY26: 3.7%
  • Net Profit Margin, Q2 FY27: 5.2%
MetricCurrentQ2 FY27Same quarter LYQ2 FY26
Revenue (₹ Cr)
96.0YoY +45%
66.0
Profit (₹ Cr)
5.0YoY +150%
2.0
Net Profit Margin
5.2%YoY +73%
3.0%

The margin engine: OTC brands take the wheel

Management, cited in reports from StockFin and Multibagger.ai, attributes the sharp margin expansion to a larger contribution from its own OTC brands. This shift to higher-margin sales more than offset a 100% year-on-year rise in depreciation and a ₹0.46 crore exceptional loss from a plant fire in April.

The underlying operational strength is clear. Reports note that adjusted for the fire loss, profit growth was even stronger at about 173% year-on-year. This operational leverage is the core of the story, not one-off gains.

Funding a growth sprint

This growth is capital-intensive. Borrowings rose to ₹57.15 crore by September, according to MarketPing, funding a 35% expansion in tablet manufacturing capacity and swelling working capital. Operating cash flow was negative ₹10.44 crore for the half-year as inventories and receivables built up to support the sales ramp.

Live Chart

· ASTONEALAB

(BSE)

ISIN: INE0TG901011

The company's guidance, reported by StockFin, sets a high bar: revenue of ₹215 crore or more for FY27, implying a 45% full-year growth rate from FY26. This requires a larger second half, but management points to delayed September dispatches due to regulatory audits as a near-term catalyst for Q3.

Key Points

  • Net profit surged 150% year-on-year on a 45.5% revenue increase, driven by operating leverage.
  • Margin expansion to 5.2% was fueled by a strategic shift towards higher-margin own OTC brands.
  • Management targets FY27 revenue of ₹215 crore+, supported by a 35% capacity increase and export pipeline development.
  • Growth is funded by increased debt, with working capital absorbing cash as the business scales rapidly.

Hexa Perspective

Astonea Labs is in a high-investment phase, trading cash flow for market share and brand building. The margin expansion proves the model works when OTC sales rise, but the sustainability of this leap hinges on executing the ambitious second-half revenue target.

The stock's 10% jump on results day, per MarketPing, reflects approval of the operational beat. The risk is that the valuation, at a significant premium to the industry, already prices in the multi-year growth guidance. Execution on exports and managing the debt-funded balance sheet will determine if the current momentum is the start of a new trend or a peak.

Share or follow HexaWealth

Also read

Want this applied to your portfolio?

Talk to a HexaWealth advisor, or sync your mutual fund data for insights tailored to your holdings.

Astonea Labs (ASTONEALAB) Q2 FY27 results, revenue and profits.

Frequently asked questions

What were Astonea Labs' Q2 FY27 results?
Astonea Labs reported Q2 FY27 revenue of ₹96 crore, a 45.5% increase year-on-year. Net profit for the quarter was ₹5 crore, surging 150% from the same period last year. The net profit margin expanded to 5.2%, up 220 basis points, indicating strong operational performance.
Why did Astonea Labs' profit jump 150% in Q2 FY27?
Astonea Labs' profit jumped due to a powerful combination of 45.5% revenue growth and significant margin expansion. Management, cited in reports, attributed the margin improvement to a larger share of sales coming from its own, higher-margin over-the-counter (OTC) brands, driving operating leverage.
What is Astonea Labs' revenue guidance for FY27?
Astonea Labs management has guided for revenue of ₹215 crore or more for FY27, as reported by StockFin. This target implies approximately 45% growth over the FY26 revenue base and is supported by expanded capacity and a growing export pipeline.
Did a one-off item affect Astonea Labs' Q2 FY27 profit?
Yes, but it reduced reported profit. The company booked an exceptional loss of ₹0.46 crore related to an uninsured inventory loss from a plant fire in April 2026. Reports from Stockwatch.live note that adjusting for this one-off, the underlying profit growth was even stronger at about 173% year-on-year.
How did Astonea Labs' stock react to the Q2 FY27 results?
According to MarketPing, Astonea Labs' stock rose 10.0% on the reaction day following the November 14 announcement. By the next day's close, the cumulative gain was 18.1%, significantly outperforming the pharmaceuticals sector median, which declined over the same period.
What is the update on Astonea Labs' working capital and cash flow?
Working capital increased to support growth, with inventories at ₹43.57 crore and receivables at ₹53.32 crore as of September 2026. For H1 FY27, operating cash flow was negative ₹10.44 crore, as reported by MarketPing, reflecting the cash absorbed by this rapid business expansion.
What are Astonea Labs' major capex plans?
Astonea Labs is funding expansion, including a completed 35% increase in tablet manufacturing capacity. Reports from mcapital.in indicate gross borrowings rose to ₹57.15 crore to fund this growth and working capital needs, with further capex expected for plant and export scale.
Are there any pending regulatory inspections at Astonea Labs' plants?
In its H1 update, the company noted that five regulatory audits in September 2026 temporarily slowed plant operations. According to Multibagger.ai, Ghana has completed a plant inspection, while inspections in Ethiopia and Kenya are expected shortly.
How is Astonea Labs building its export business?
Astonea Labs is expanding its export network, appointing new distributors in Guatemala and Panama to reach nine Latin American and Caribbean markets. The company has filed 95 product dossiers across several countries and expects around 60 export registrations in Q1 FY28, as per company reports.
What was Astonea Labs' EBITDA margin in Q2 FY27?
Astonea Labs reported a consolidated EBITDA margin of 13.4% for Q2 FY27, according to MarketPing. This represents a significant expansion from the year-ago period, aligning with the company's full-year guidance targeting an EBITDA margin between 13% and 15%.
Astonea Labs Q2 FY27 results net profit
Astonea Labs reported a consolidated net profit of ₹4.82 crore for Q2 FY27, according to filings cited by MarketPing. This marked a 153.3% increase compared to the net profit in H1 of the previous fiscal year, showcasing dramatic earnings growth.
Why did Astonea Labs profits surge?
Astonea Labs' profits surged due to a 44.6% rise in H1 revenue and a major expansion in profitability. The driver was a favorable sales mix shift, with a larger contribution from the company's own over-the-counter brands, which carry higher margins than contract manufacturing.